The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Mar 2017 10:54

RNS Number : 7446Y
Faron Pharmaceuticals Oy
07 March 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Faron Pharmaceuticals Oy

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Yes

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

 

Legal & General Group Plc (L&G)

 

Legal & General (Unit Trust Managers) Limited (UTM)

 

4. Full name of shareholder(s)  (if different from 3.):

 

N/A

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

03 March 2017

6. Date on which issuer notified:

07 March 2017

7. Threshold(s) that is/are crossed orreached:

 

UTM (Below 5%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD NPV

1,365,000.00

 Below 5%

-

 Below 5%

-

 Below 5%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

 

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

 UTM

(Below 5%)

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 1,565,000 - 5.64%= Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 1,565,000 - 5.64%= Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 1,565,000 - 5.64%= Total Position)

Legal & General (Unit Trust Managers) Limited (Below 5% = UTM)

Legal & General Group Plc (Direct) (L&G) ( Below 3% = LGAS, & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH) (LGAS)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

 

 

 

 

13. Additional information:

Notification using the total voting rights figure of  27,734,044

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLKMGGFGNMGNZM
Date   Source Headline
4th Oct 20197:20 amRNSNotice of EGM
2nd Oct 20197:00 amRNSUpdate on Traumakine drug substance manufacturing
30th Sep 20197:00 amRNSMATINS poster presentation at ESMO Congress
25th Sep 20199:13 amRNSHoldings in Company
23rd Sep 20197:08 amRNSInterim results
2nd Sep 20197:00 amRNSMATINS study selected for ESMO 2019
27th Aug 20197:00 amRNSResult of Open Offer and Further Subscription
19th Aug 20199:33 amRNSHolding(s) in Company
16th Aug 20197:00 amRNSNotice of Interim Results
6th Aug 20191:53 pmRNSIssue of Equity
5th Aug 20197:00 amRNSSubscription and Open Offer
12th Jul 20197:00 amRNSMATINS study update
5th Jul 20199:00 amRNSPrice Monitoring Extension
4th Jul 20194:40 pmRNSSecond Price Monitoring Extn
4th Jul 20194:35 pmRNSPrice Monitoring Extension
4th Jul 20192:00 pmRNSPrice Monitoring Extension
4th Jul 20199:31 amRNSHoldings in Company
1st Jul 201912:10 pmRNSGrant of options
26th Jun 20197:00 amRNSPhase II INFORAAA study update
14th Jun 20197:00 amRNSFinal results from YODA study
28th May 201912:27 pmRNSResults of AGM
24th May 20199:32 amRNSAGM update, Board & management changes
22nd May 201912:51 pmRNSGrant of Options
21st May 20199:21 amRNSHolding(s) in Company
16th May 20199:16 amRNSHolding(s) in Company
14th May 20197:01 amRNSHoldings in Company
14th May 20197:00 amRNSShare Subscription and Issue of Equity
7th May 20197:05 amRNSNotice of AGM
7th May 20197:00 amRNSFinal Results for the year ended 31 December 2018
2nd May 20195:20 pmRNSStatement regarding Price Movement
2nd May 20192:05 pmRNSSecond Price Monitoring Extn
2nd May 20192:00 pmRNSPrice Monitoring Extension
29th Apr 20197:00 amRNSResults from the Japanese Phase III study
25th Apr 20194:09 pmRNSHolding(s) in Company
12th Apr 20191:20 pmRNSHolding(s) in Company
11th Apr 20197:00 amRNSFirst expansion cohort for MATINS trial part 2
10th Apr 201911:41 amRNSHolding(s) in Company
5th Apr 20197:00 amRNSNotice of Results
2nd Apr 20199:23 amRNSHoldings in Company
29th Mar 20197:00 amRNSHolding(s) in Company
28th Mar 201912:54 pmRNSResults of the Placing and Subscription
26th Mar 20193:31 pmRNSResult of Placing and Issue Price
26th Mar 20197:00 amRNSProposed Placing to raise approximately EUR 3m
21st Feb 20197:00 amRNSMATINS study update
13th Feb 20198:57 amRNSNew data published by Clinical Cancer Research
19th Dec 20187:00 amRNSTraumakine update - YODA results
14th Dec 201811:20 amRNSFirst patient dosed in phase I/II MATINS study
11th Dec 20184:26 pmRNSHolding(s) in Company
5th Dec 20187:00 amRNSPatient subgroup identified from INTEREST trial
3rd Dec 20187:00 amRNSFaron receives CTA approval for Clevegen

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.